 |
|
|
| |
Pharmacokinetics and exploratory exposure-response of siRNAs administered monthly as ARB-001467 (ARB-1467) in a Phase 2a study in HBeAg positive and negative virally suppressed subjects with chronic hepatitis B
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Timothy Eley1, Robert Russ1, Adrian Streinu-Cercel6, Edward J. Gane2, Stuart K. Roberts3, Sang Hoon Ahn4, Yoon Jun Kim5, William Symonds1, Patricia Mendez1
1Arbutus Biopharma Corporation, Burnaby, BC, Canada; 2Auckland Clinical Studies Limited, Auckland, New Zealand; 3The Alfred, Melbourne, VIC, Australia; 4Yonsei University College of Medicine, Seoul, Korea (the Republic of); 5Seoul National University College of Medicine, Seoul, Korea (the Republic of); 6Carol Davila University of Medicine and Pharmacy, Prof. Dr. MateiBals National Institute for Infectious Diseases
1.https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html;
2.WHOGlobal HepatitisReport2017
3.Streinu-CercelA,et al. JHepatol2017;66(suppl1):S688-S689 (NCT02631096)
|
| |
|
|
|
|
|
